Search results for "From ACP Journal Club"
Patients surviving COVID-19 had increased risk for incident diabetes vs. persons without COVID-19
Although the effect of COVID-19 on diabetes incidence is small, according to the study, the affected population could be large, given that many at-risk people have had acute COVID-19, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/08/12/7.htm
12 Aug 2022
In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors
A cohort study's finding of increased risk of diabetic ketoacidosis with sodium-glucose cotransporter-2 (SGLT2) inhibitors is relevant to clinical decision making, but not definitive given the limitations of observational research, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/01/08/6.htm
8 Jan 2021
Review compares effectiveness, cost, and safety of second-line drugs for diabetes
The review found that sulfonylureas were more cost-effective than newer agents, but an ACP Journal Club commentary stressed the importance of shared decision making in the choice of a second agent.
https://diabetes.acponline.org/archives/2018/02/09/6.htm
9 Feb 2018
In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA1c or significant/severe hypoglycemia
An ACP Journal Club commentary pointed out that use of once-weekly insulin for patients with type 2 diabetes will require more cautious dose-titration algorithms and less stringent glycemic targets to avoid hypoglycemia.
https://diabetes.acponline.org/archives/2021/03/12/7.htm
12 Mar 2021
GLP-1 RA plus SGLT-2 inhibitor vs. either drug alone reduces HbA1c and SBP
The finding that combining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors improves glycemic control and systolic blood pressure (SBP) without increasing hypoglycemia is important, but additional cost-effectiveness research on the drugs is needed, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/12/11/9.htm
11 Dec 2020
Intensive glucose-lowering in type 2 diabetes was linked to hypoglycemia in high-complexity patients
More than 20% of patients with type 2 diabetes received treatment more intensive than that recommended by HbA1c-based guidelines, a study of Medicare patients found.
https://diabetes.acponline.org/archives/2016/10/07/5.htm
7 Oct 2016
In obesity with T2DM, biliopancreatic diversion increased T2DM remission vs. medical and lifestyle therapy at 10 y
Previous research has shown short-term remission of type 2 diabetes after bariatric surgery, but a decade of data from this randomized trial should reassure patients of the favorable long-term benefits and safety of this intervention, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/06/11/9.htm
11 Jun 2021
Review: Rapid-acting analogues do not differ from regular human insulin for mortality or HbA1c in type 2 diabetes
The review shows that, contrary to specialty recommendations, there is no reason not to use regular human insulins, which are less costly than analogue insulins, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/05/10/7.htm
10 May 2019
SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes
Diabetic ketoacidosis (DKA) is rare with sodium-glucose co-transporter-2 (SGLT2) inhibitors but more common than with control medications, and clinicians should be vigilant in identifying euglycemic DKA in patients on these drugs, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/11/13/6.htm
13 Nov 2020
In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs
A meta-analysis identified relative benefits of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) based on individual cardiovascular and renal risks.
https://diabetes.acponline.org/archives/2021/06/11/8.htm
11 Jun 2021